ClinicalTrials.gg
Active, not recruitingNCT03506308AVPASUpdated Mar 18, 2026

Post Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteriovenous Fistulae

An interventional study of LUTONIX 035 Drug Coated Balloon PTA Catheter in Arteriovenous Fistula, sponsored by C. R. Bard. Active, not recruiting at 26 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by C. R. Bard (part of Becton, Dickinson and Company) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
213
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Arteriovenous Fistula by Becton, Dickinson and Company — 1 open to participants now, 2 under way, none of them phase 3. Arteriovenous Fistula · Becton, Dickinson and Company.

Started
2018
the only one that year
No phase
8 of 10
1 open now
Registered
7th of 10
by date

Among the 10 studies in Arteriovenous Fistula by Becton, Dickinson and Company, this one is the only one that started in 2018, is one of 8 with no phase, and was the 7th registered.

Arteriovenous Fistula

248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.

Browse Arteriovenous Fistula studies →

Open to participants now

1 of the 10 studies in Arteriovenous Fistula by Becton, Dickinson and Company is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 27 Arteriovenous Fistula studies recruiting now, 13 (48%) set no upper age limit and 4 (15%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Arteriovenous Fistula by Becton, Dickinson and Company, or all of them as a file.
02

Study summary

This prospective, global, multicenter, single arm post-approval study is designed to investigate the clinical use and safety of the Lutonix® 035 AV Drug Coated Balloon (DCB) PTA Catheter in subjects presenting with clinical and hemodynamic abnormalities in native arteriovenous (AV) fistulae located in the upper extremity.

Read the detailed description

This post-market approval study (PAS) is required by the FDA as a condition of approval for the Lutonix drug coated balloon catheter. It is intended to demonstrate safety and assess the clinical use and outcomes of the LUTONIX Catheter in dysfunctional arteriovenous fistulae (AVF) in a heterogeneous patient population in real world clinical practice.

03

Conditions studied

  • Arteriovenous Fistula

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or non-pregnant, non-breastfeeding female ≥18 years of age
  2. Subject is willing to provide , and is willing to comply with the protocol-required follow up visits
  3. Target lesion must be a mature arteriovenous fistula located in the arm presenting with any clinical, physiological or hemodynamic abnormalities warranting angiographic imaging as defined in the K/DOQI guidelines
  4. Subject has a target lesion that can be treated with available LUTONIX DCB according to the Instructions For Use (IFU)
  5. Venous stenosis of an AV fistula in which the target lesion is located from the anastomosis to the axillosubclavian junction, as defined by insertion of the cephalic vein
  6. Successful pre-dilation of the target lesion with an uncoated percutaneous transluminal angioplasty (PTA) balloon defined as:

    1. No dissection;
    2. No extravasation requiring treatment;
    3. Residual stenosis ≤30% by angiographic measurement;
    4. Ability to completely efface the waist using the pre-dilation balloon.

Exclusion criteria

Exclusion Criteria:

  1. Subject is currently participating in an drug, biologic, or device study, or previous enrollment in this study
  2. Subject has a non-controllable allergy to contrast
  3. Subject has another medical condition that, in the opinion of the Investigator, may confound the data interpretation or is associated with a insufficient to allow for completion of subject study procedure and follow up
  4. Target lesion is located central to the axillosubclavian junction
  5. A thrombosed access or an access with a thrombosis treated ≤7 days before to the index procedure
  6. Prior surgical interventions of the access site ≤30 days before the index procedure
  7. Target lesion is located within a bare metal or covered stent
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
213 participants (estimated)

Study arms

  • Other
    LUTONIX 035 Drug Coated Balloon PTA Catheter

    This is a single-arm study. All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.

    Device: LUTONIX 035 Drug Coated Balloon PTA Catheter

Interventions

  • DeviceLUTONIX 035 Drug Coated Balloon PTA Catheter

    All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Target Lesion Primary Patency (TLPP)

    TLPP is defined as the interval following index procedure intervention until clinically driven reintervention of the target lesion or access thrombosis.

    Time frame: 6 Months

  2. Percentage of Participants With No Primary Safety Events

    Primary safety events include any serious adverse event(s) involving the AV access circuit through 30 days

    Time frame: 30 days

Secondary outcomes

  1. Percentage of Participants With Target Lesion Primary Patency

    TLPP is defined as the interval following index procedure intervention until clinically driven reintervention of the target lesion or access thrombosis.

    Time frame: 12, 18, 24 Months

  2. Number of re-interventions required to maintain target lesion patency

    Clinically driven reintervention is defined as a lesion that has ≥ 50% stenosis and at least one clinical, physiological or hemodynamic abnormality attributable to the stenosis defined in the K/DOQI guidelines.

    Time frame: 6, 12, 18, 24 Months

  3. Percentage of Participants With Access Circuit Primary Patency (ACPP)

    Access circuit is defined as the area from the AV access anastomosis to the superior vena cava-right atrial junction.

    Time frame: 6, 12, 18, 24 Months

  4. Number of re-interventions required to maintain access circuit patency

    Clinically driven reintervention is defined as a lesion that has ≥ 50% stenosis and at least one clinical, physiological or hemodynamic abnormality attributable to the stenosis defined in the K/DOQI guidelines.

    Time frame: 6, 12, 18, 24 Months

  5. Percentage of Participants With Device, Procedural, and Clinical Success

    Device Success: Successful delivery to the target lesion, deployment, and retrieval at index procedure. Procedural Success: At least one indicator of hemodynamic success (e.g., physical examination with restoration of a thrill, direct measurement of flow) in the absence of peri-procedural (index procedure and through hospital stay) Serious Adverse Device Effects (SADEs). Clinical Success: The resumption of dialysis for at least one session after the index procedure.

    Time frame: 24 Months

  6. Percentage of Participants With Abandonment of Permanent Access in the Index Extremity

    The arteriovenous fistula / access circuit is considered abandoned when it is no longer being used for dialysis because the access was not functioning.

    Time frame: 6, 12, 18, 24 Months

  7. Percentage of Participants With Secondary Patency of the Access Circuit

    Survival of patency of access circuit from the time of intervention until access abandonment or achievement of a censored event (death, transfer to another hemodialysis unit, transfer to peritoneal dialysis, transplantation, and end of study period), and includes all surgical and endovascular interventions.

    Time frame: 6, 12, 18, 24 Months

  8. Time to loss of target lesion secondary patency following DCB intervention

    Time between first reintervention with the DCB to the next loss of patency

    Time frame: 24 Months

  9. Percentage of Participants With Freedom from any Serious Adverse Event(s) Involving the AV Access Circuit

    Safety events include any serious adverse event(s) involving the AV access circuit

    Time frame: 6, 12, 18, 24 Months

  10. Percentage of Participants With Device and Procedure Related Adverse Events

    Freedom from device-related or procedure-related serious adverse events

    Time frame: 6, 12, 18, 24 Months

Other outcomes

  1. Vital status of participants

    All cause death

    Time frame: 36, 48, and 60 Months

07

Study locations

26 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2018 (actual). Primary completion is estimated for Apr 2027, 104 months after the start.

Of 84 interventional studies with no phase under Arteriovenous Fistula, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 43. This study's planned 104 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2018
First posted
Apr 24, 2018
StartActual
Aug 7, 2018
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2030
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03506308
Lead sponsor
C. R. Bard
Responsible party
Sponsor
First posted
Apr 24, 2018
Start date
Aug 7, 2018
Primary completion
Apr 2027 (estimated)
Completion
Apr 2030 (estimated)
Last update
Mar 18, 2026

Study contacts

Scott Trerotola, MD
principal investigator · Hospital of the University of Pennsylvania; Division of Interventional Radiology
Dheeraj Rajan, MD
principal investigator · University Health Network; Division of Vascular & Interventional Radiology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion